As per GOI’s circular on price-capping of stents by NPPA(National Pharmaceutical Pricing Authority), new prices of coronary stents have been implemented effective 14th February, 2017. For details on stent pricing, across our hospitals. CLICK HERE

Hematopoietic Stem Cell Transplant (HSCT Treatment) for Multiple Sclerosis at at Fortis Memorial Hospital (FMRI), Gurgaon India

Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and in which an abnormal response of the body’s immune system is directed against the central nervous system (CNS), which is made up of the brain, spinal cord and optic nerves. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease.


HSCT or Hematopioetic Stem Cell Transplant is now a scientifically proven treatment, that has shown positive results to halt disease progression of Multiple Sclerosis. It is not a new procedure as such, as it has been used to treat cancer since the 1960’s, but it is a relatively new treatment for MS. The aim of AHSCT is to ‘reset’ the immune system to stop it from attacking the central nervous system. The procedure involves removing the harmful immune cells that attack the brain and spinal cord in MS, and then uses a person’s own stem cells to effectively re-grow the immune system. The aim is that re-booting the immune system in this way will prevent further damage in the brain and spinal cord.

How does the HSCT  Treatment Work?

The goal of AHSCT is to reset the patient’s  immune system to stop it from attacking nerve cells in your body. During the treatment, doctors collect bone marrow stem cells from the blood and freeze them. These "haematopoietic stem cells" are at such an early stage of development that they haven't acquired the flaws that trigger MS. The faulty immune system is then destroyed using chemotherapy. The thawed-out stem cells are re-infused into the patient’s blood to reboot the immune system.

Recent studies have shown that in  patient’s e with relapsing-remitting multiple sclerosis, AHSCT was linked to a significant reduction in disability on average. Eighty percent of the people treated who were followed for 4 years had no more relapses, and 87% had no worsening of their level of disability.

HSCT Treatment at Fortis Memorial Hospital, Gurgaon India

The method for Autologous stem cell transplant for MS which is followed in Fortis  Hospital comprises of Cyclosphosphamide and ATG. These agents act as lymphoablative drugs. In addition the protocol has provision for Rituximab to reduce risk of EBV reactivation.

The total duration of uncomplicated stay in in India is about 24 to 28 days and the best part is that  patients are managed on an inpatient basis in our world class hospital at Gurgaon near the New Delhi, the capital of India.

HSCT Medical Team At Fortis Memorial Research Hospital, India

 

Dr Rahul Bhargava MD, DM (Hematology) AIIMS

Head & Senior Consultant – Hematology- Oncology and Bone Marrow Transplant.


Dr Rahul Bhargava has pioneered HSCT for MS in India and  is known for excellent patient outcomes and this has earned him the reputation of being among the best of his generation in this field of specialisation. He has trained Christian Medical College, Vellore – a centre widely regarded as the cradle of hematology and bone marrow transplantation in India – under the famed Prof. Mammen Chandy, he then moved to the All India Institute of Medical Sciences (AIIMS) in New Delhi for a formal three-year superspecialist degree of DM in Clinical Hematology. Subsequently, Dr. Bhargava was selected for a fellowship in Vancouver, Canada, and underwent specific training in voluntary stem cell and umbilical cord transplantation. The Hematology and HSCT facility set up by him at Fortis Hospital is truly word class and has its own transplantation unit and extensive laboratory facilities, providing cutting-edge clinical skills and the latest in technology at affordable costs for transplantation and other hematological services. Till date, Dr. Bhargava has performed close to 300  bone marrow transplants

Dr Praveen Gupta MD, DM (Neurology)

Director & Head  – Neurology


Dr. Praveen Gupta is among th emost renowned and experiencesd specialists in India and  has established Neurology practice in three large corporate hospitals before he joined Fortis Hospitals.He has to his credit the achievment of starting first stroke centre in Gurgaon and first to use solitaire for mechanical thrombolysis also started DBS in Gurgaon and DBS for epilepsy in Asia. He is frequently invited speaker at National and International conferences.


Dr Gupta is the Director and Head of Fortis Neuroscience centre that provides most advanced intervention management of stroke, stroke rehabilitation, cerebral palsy, advanced second line management for multiple scelerosis, epileptic surgery,  DBS surgery for Parkinson patients.

 

 

For more details about the HSCT Treatment at Fortis Hospital, India please contact us by email on hsct@fortishealthcare.com